Business
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"Launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis Achieved $1.7 million in net product sales with more than 1,700 dispensed bottles Strengthened balance sheet with an approximately $100 million public equity offering Management to host conference call today, November 9, 2023, at 1:30 p.m. P.T. / 4:30 p.m. E.T. IRVINE, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the third quarter ended September 30, 2023, and recent business achievements. “We are proud to be able to bring XDEMVY to the millions of people suffering from Demodex blepharitis, who, until recently, have been living without an effective, FDA-approved treatment option,” said Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “The XDEMVY launch is off to a strong start and we are encouraged by the early momentum among eye care providers and patients we have generated in just the first few weeks of availability.” Recent Business Highlights On July 24, XDEMVY® was approved by the U.S. Food and Drug Administration (FDA) as the first and only therapeutic for Demodex blepharitis (DB), a highly prevalent eyelid disease that impacts approximately 25 million eye care patients in the U.S. It was approved a month prior to the PDUFA date and launched on August 24. XDEMVY targets the root cause of DB and in pivotal trials demonstrated significant improvement in eyelids (reduction of collarettes, the pathognomonic sign of the disease, to no more than 2 collarettes per upper lid), mite eradication (mite density of 0 mites per lash) and erythema cure (Grade 0). Saturn-2 data were delivered as encore presentations at the American Academy of Optometry and American Academy of Ophthalmology conferences.XDEMVY was added to the American Academy of Ophthalmology’s Preferred Practice Pattern (PPP) guidelines as the first and only FDA-approved therapeutic for the treatment of Demodex blepharitis.In the third quarter of 2023: XDEMVY generated $1.7 million in net product sales~1,700 bottles of XDEMVY were delivered to patientsRecognized a better than anticipated gross-to-net discount of 73%. The Com...